Patents by Inventor Reiko Matsuyama

Reiko Matsuyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10774321
    Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 15, 2020
    Assignee: KM BIOLOGICS CO., LTD.
    Inventors: Hiroshi Nakatake, Masaki Hirashima, Hideki Takeo, Reiko Matsuyama, Wataru Morikawa
  • Publication number: 20200140843
    Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.
    Type: Application
    Filed: January 14, 2020
    Publication date: May 7, 2020
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Hiroshi NAKATAKE, Masaki HIRASHIMA, Hideki TAKEO, Reiko MATSUYAMA, Wataru MORIKAWA
  • Publication number: 20170081654
    Abstract: A method for monomerization of MMP-7 aggregates is provided. A method for monomerization of MMP-7 aggregates which comprises treating MMP-7 aggregates with a buffer solution comprising a monovalent cation chloride (sodium chloride, potassium chloride, etc.) at a low concentration or with a buffer solution not comprising a monovalent cation chloride, a process for preparing MMP-7 which involves said method for monomerization, and a (pharmaceutical) composition comprising MMP-7 in the aforementioned buffer solution. In case that a (pharmaceutical) composition comprising MMP-7 at a low concentration is prepared, the aforementioned buffer solution comprising sugar alcohols or sugars is used.
    Type: Application
    Filed: May 20, 2015
    Publication date: March 23, 2017
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Hiroshi NAKATAKE, Masaki HIRASHIMA, Hideki TAKEO, Reiko MATSUYAMA, Wataru MORIKAWA
  • Patent number: 8283137
    Abstract: When genes encoding three kinds of proteins constituting fibrinogen, an ? chain (or variant of ? chain), a ? chain and a ? chain (or variant of ? chain) are incorporated into an animal cell, a constitutional ratio of respective genes is such that a ? chain (and/or variant of ? chain) gene is an equal amount to a 1000-fold amount relative to an ? chain (and/or variant of ? chain) gene and a ? chain gene and, further, by using a baculovirus P35 gene, a recombinant fibrinogen highly producing cell is prepared.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: October 9, 2012
    Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
    Inventors: Reiko Matsuyama, Hiroaki Maeda
  • Patent number: 7829306
    Abstract: A gene encoding a production amount-potentiating factor is introduced into an animal cell to transform the cell. Alternatively, a protein production gene and the gene encoding the production amount-potentiating factor are introduced into the animal cell to transform the cell. Herein, as the production amount potentiating factor, there is used a factor having caspase activity inhibiting activity and/or protein biosynthesis activity potentiating action, for example, baculovirus P35. Further, the animal cell is cultured by a culturing method under a condition that apoptosis is not induced, so that a protein is mass-produced.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: November 9, 2010
    Assignee: Juridical Foundation the Chemo-Sero-Therapeutic Research Institute
    Inventors: Reiko Matsuyama, Hiroaki Maeda, Hitomi Shirahama, Takayuki Imamura, Yasuharu Kamachi
  • Publication number: 20100151522
    Abstract: When genes encoding three kinds of proteins constituting fibrinogen, an ? chain (or variant of ? chain), a ? chain and a ? chain (or variant of ? chain) are incorporated into an animal cell, a constitutional ratio of respective genes is such that a ? chain (and/or variant of ? chain) gene is an equal amount to a 1000-fold amount relative to an ? chain (and/or variant of ? chain) gene and a ? chain gene and, further, by using a baculovirus P35 gene, a recombinant fibrinogen highly producing cell is prepared.
    Type: Application
    Filed: July 28, 2004
    Publication date: June 17, 2010
    Applicant: JURIDICAL FOUNDATION THE CHEMOSERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Reiko Matsuyama, Hiroaki Maeda
  • Publication number: 20090099338
    Abstract: A gene encoding a production amount-potentiating factor is introduced into an animal cell to transform the cell. Alternatively, a protein production gene and the gene encoding the production amount-potentiating factor are introduced into the animal cell to transform the cell. Herein, as the production amount potentiating factor, there is used a factor having caspase activity inhibiting activity and/or protein biosynthesis activity potentiating action, for example, baculovirus P35. Further, the animal cell is cultured by a culturing method under a condition that apoptosis is not induced, so that a protein is mass-produced.
    Type: Application
    Filed: October 21, 2004
    Publication date: April 16, 2009
    Applicant: JURIDICAL FOUNDATION THE CHEMO-THERAPEUTIC RESEARC
    Inventors: Reiko Matsuyama, Hiroaki Maeda, Hitomi Shirahama, Takayuki Imamura, Yasuharu Kamachi